MITOGEN-ACTIVATED PROTEIN INHIBITORS: FULL-FIELD ELECTRORETINOGRAM DEMONSTRATING GENERALIZED RETINAL DYSFUNCTION

Michel van Lint1, Herlinde Ebraert2, Elisabeth H Van Aken3

  • 1Department of Ophthalmology, Brussels University Hospital, Jette, Belgium. Dr. van Lint is now with the Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium.

Abstract

Insights

Mitogen-activated protein inhibitors like trametinib can cause widespread retinal toxicity. Reducing the dosage may improve vision and resolve retinal detachments, aiding in understanding these effects.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Oncology

Background:

  • Mitogen-activated protein (MAP) kinase inhibitors are used in cancer therapy.
  • Retinal toxicity is a known side effect of some targeted therapies.

Observation:

  • A patient treated with the MAP kinase inhibitor trametinib developed generalized retinal toxicity.
  • Full-field electroretinogram (ffERG) revealed widespread retinal dysfunction.

Findings:

  • Trametinib-induced retinal toxicity manifested as generalized dysfunction, not solely posterior pole involvement.
  • Decreasing the trametinib dosage led to improved ffERG responses and resolution of serous detachments.

Implications:

  • MAP kinase inhibitors may impact global retinal function.
  • Understanding these mechanisms is crucial for managing ocular side effects in patients receiving targeted therapies.
  • This case highlights the importance of ffERG in detecting and monitoring diffuse retinal toxicity.

Related Concept Videos